Document:

MUTUAL CONFIDENTIALITY AND NON-DISCLOSURE AGREEMENT

         THIS CONFIDENTIALITY AND NON-DISCLOSURE  AGREEMENT (the "Agreement") is
entered  into  by and  between  VIRAGEN,  INCORPORATED  ("VIRAGEN"),  a  Florida
corporation, having a principal place of business at 865 S.W. 78th Avenue, Suite
100,  Plantation,  Florida 33324,  and BIOSYNTECH LTD.  ("BIOSYNTECH",  having a
principal place of business at 475 Boulevard Armand  Frappier,  Laval QC, Canada
H7V 4b3.

         WHEREAS, BIOSYNTECH is in the business of developing, manufacturing and
marketing the  BST-GEL(TM) and  BST-CARGEL(TM)  advanced  big-materials  used in
drug,  cell and gene delivery  systems,  big-engineered  artificial  tissues and
injectable self-forming implants; and

         WHEREAS,  VIRAGEN is in the  business  of  manufacturing  and  clinical
development of biological response modifiers, including interferons; and

         WHEREAS, VIRAGEN and BIOSYNTECH (the "Parties") are willing to disclose
to each other certain confidential information for the purpose of evaluating the
possibility  of  entering  into  a  business   relationship  (which  purpose  is
hereinafter referred to as the "Purpose of this Agreement");

         NOW,  THEREFORE,  in consideration of the premises and mutual covenants
contained herein, the Parties agree as follows:

          1. CONFIDENTIAL  INFORMATION.  The term "Confidential  Information" as
used in this Agreement shall mean any and all non-public  information  disclosed
by one party (the "Disclosing Party") to the other party (the "Receiving Party")
in a written or tangible form (including fax transmissions, electronic mail, and
electronic media) clearly marked (or, in the case of electronic media, otherwise
clearly identified) as being  confidential,  and relating to the Purpose of this
Agreement.   Confidential  Information  shall  expressly  include  any  and  all
information derived from the foregoing Confidential Information.

          2.  CONFIDENTIALITY  OBLIGATIONS.  The Receiving  Party shall keep the
Confidential Information in strict confidence,  and shall not disclose it to any
person, fun or corporation, nor use the Confidential Information for any purpose
other than for the specific

                                      -1-

<PAGE>

Purpose of this  Agreement  without the prior written  consent of the Disclosing
Party.  The  Receiving  Party  shall  protect  and  safeguard  the  Confidential
Information  furnished by the Disclosing Party by using the same degree of care,
but no less than a reasonable  degree of care, to prevent the unauthorized  use,
dissemination  or publication of the  Confidential  Information as the Receiving
Party uses to protect its own confidential or proprietary  information of a like
nature.  The  Receiving  Party shall limit the  disclosure  of the  Confidential
Information  to only such officers,  employees or agents of the Receiving  Party
who need to know such  information  in order to  accomplish  the Purpose of this
Agreement.  The  Receiving  Party  agrees  that all such  officers,  agents  and
employees  shall be  notified  of the  proprietary  nature  of the  Confidential
Information

         3.  EXCEPTIONS.   The  obligations  of  confidentiality   contained  in
Paragraph 2 shall not apply to any information which:

            (a)  is  proven  by  written  evidence  to have  been  known  to the
Receiving Party at the time of disclosure; or

            (b)  is or becomes  publicly  known or  available  through no act or
fault of the Receiving Party; or

            (c)  is rightly  received by the Receiving  Party from a third party
who was authorized to disclose such information; or

           (d)  is  proven  by  written  evidence  to have  been  independently
developed by the Receiving Party; or

           (e)  is  approved  for  release  by  written  authorization  of  the
Disclosing Party; or

          (f)  is  disclosed  by the  Receiving  Party  pursuant to law or any
governmental or court order,  provided that the Receiving Party shall first have
given notice to the Disclosing Party of such order and made a reasonable  effort
to obtain a protective order.

     4.   DURATION. The obligations of confidentiality  contained in Paragraph 2
shall extend for a period of five (5) years from the date of  disclosure of such
information.

     5.   RETURN OF DOCUMENTS.  Upon the written request of the Disclosing Party
at any time,  the Receiving  Party shall  immediately  return to the  Disclosing
Party all  written  Confidential  Information  except for one copy for  archival
purposes which will be kept by the General Counsel of the Receiving Party.

                                      -2-

<PAGE>

     6.   RELATION BETWEEN PARTIES. At all times, Confidential Information shall
be and remain the property of the  Disclosing  Party.  This  Agreement  does not
grant  either  party any  express  or  implied  rights  under the other  party's
patents, know-how, trade secrets,  copyrights,  trademarks or other intellectual
property rights or  applications  therefor.  The Parties make no  representation
that any type of  business  relation  will be  concluded  between  the  Parties.
Nothing  in this  Agreement  shall be deemed to  create a  partnership  or joint
venture between the Parties.

     7.   MISCELLANEOUS.  This  Agreement  shall be governed by and construed in
accordance with the laws of the State of Florida. This Agreement constitutes the
complete  agreement of the Parties and supersedes  all previous  understandings,
agreements  or  representations,  written or oral,  between  the Parties to this
Agreement. This Agreement may not be amended except by written instrument signed
by both  Parties.  In the event that any one or more of the  provisions  of this
Agreement is unenforceable, the enforceability of the remaining provisions shall
be unimpaired.

          IN WITNESS WHEREOF, the Parties hereto have executed this Agreement in
duplicate on the date(s) set forth below.

BIOSYNTECH, LTD.                           VIRAGEN, INC.

By: /s/ Francois Binette                   By: /s/ Mel Rothberg
    ------------------------                   --------------------

Name:     Francois Binette                 Name:     Mel Rothberg

Title:    V.P. R&D                         Title:    Executive V.P.

Date:     9/20/99                          Date:     8/30/99CONFIDENTIAL DISCLOSURE AGREEMENT

         This  agreement,  effective as of October 26, 1999  between  Biosyntech
Limited,  having its place of business at 475, Boul.  Armand-Frappier,  Montreal
(Laval) QC Canada H7V 4B3("Company"), and Ontogeny, Inc., a Delaware corporation
having  its  place  of  business  at 45  Moulton  Street,  Cambridge,  MA  02138
("Ontogeny").

         1. BACKGROUND. Company and Ontogeny intend to engage in discussions and
negotiations  concerning the  establishment of a business  relationship  between
them. In connection with such  discussions and  negotiations,  it is anticipated
that Company may disclose or deliver to Ontogeny certain of its trade secrets or
confidential  or  proprietary  information  in the field of  Gel-based  delivery
systems  (the  "Company  Field") and that  Ontogeny  may  disclose or deliver to
Company certain of its trade secrets or confidential or proprietary  information
in the field of  growth/inducing  factors (the "Ontogeny Field") for the purpose
of  enabling  the other  party to  evaluate  the  feasibility  of such  business
relationship.  The parties have  entered into this  Agreement in order to assure
the  confidentiality  of such trade  secrets  and  confidential  or  proprietary
information  in  accordance  with the terms of this  Agreement.  As used in this
Agreement,  the party disclosing  Proprietary  Information (as defined below) is
referred to as the  "Disclosing  Party";  the party  receiving such  Proprietary
Information is referred to as the "Recipient".

         2.  PROPRIETARY  INFORMATION.  As  used  in this  Agreement,  the  term
"Company  Proprietary  Information"  shall  mean any and all  information,  data
specifications,   techniques,   formulae,  manufacturing  processes,  and  other
information in or concerning  the Company Field  disclosed in writing by Company
to Ontogeny (or if orally or visually disclosed,  confirmed in writing within 30
days  of  such  disclosure)  and  designated  as  confidential.  As used in this
Agreement,  the terms "Ontogeny Proprietary  Information" shall mean any and all
information,   data,   specifications,   techniques,   formulae,   manufacturing
processes,  and any  other  information  in or  concerning  the  Ontogeny  Field
disclosed in writing by Ontogeny to Company (or if orally or visually disclosed,
confirmed  in  writing  within 30 days of such  disclosure)  and  designated  as
confidential.   Company   Proprietary   Information  and  Ontogeny   Proprietary
Information are collectively referred to herein as "Proprietary Information".

         3. TERM.  The  provisions of this  Agreement  shall remain in force for
five years from the date of this Agreement. ----

         4. DISCLOSURE OF PROPRIETARY  INFORMATION.  The Recipient shall hold in
confidence,  and shall not disclose to any person outside its organization,  any
Proprietary  Information.  The Recipient shall use such Proprietary  Information
only for the  purpose  for which it was  disclosed  and shall not use or exploit
such  Proprietary  Information  for its own  benefit  or the  benefit of another
without the prior written consent of the Disclosing  Party.  The Recipient shall
disclose  Proprietary  Information  received by it under this  Agreement only to
persons  within  its  organization  who  have a need to 'know  such  Proprietary
Information  in the course of the  performance of their duties and who are bound
to protect the confidentiality of such Proprietary Information.

         5.  LIMITATION  ON  OBLIGATIONS.   The  obligations  of  the  Recipient
specified in Section 4 above shall not apply,  and the  Recipient  shall have no
further obligations,  with respect to any Proprietary  Information to the extent
that such Proprietary Information:

<PAGE>

         (a) is known to the  public at the time of  disclosure  or  becomes  so
known  through no wrongful act on the part of the  Recipient,  but only after it
becomes so publicly known;

         (b) is in the  Recipient's  possession  at the  time of  disclosure  as
evidenced by written records;

         (c) becomes  known to the Recipient  through  disclosure by sources not
under an obligation to the  disclosing  party to maintain  such  information  in
confidence; or

         (d) is  independently  developed by or on behalf of the Recipient by an
individual or individuals not having received Proprietary Information hereunder;

Notwithstanding   the  above,   the  Recipient  may  disclose  such  Proprietary
Information as may be required to comply with  applicable  laws or  governmental
regulations, provided that the Recipient provides notice to the Disclosing Party
of this request  promptly prior to any disclosure to permit the Disclosing Party
to oppose such  disclosure by  appropriate  legal action or to evaluate  whether
means can be taken to provide such disclosure on a confidential basis.

         6. NO LICENSe. It is understood that no right to a license,  implied or
otherwise, under any patent or other rights now or hereafter owned or controlled
by the Disclosing  Party, is granted to the Recipient by this Agreement and that
the disclosure of information  does not grant any party any right in and to such
information.

         7. RETURN OF DOCUMENTS.  The Recipient shall, upon the request of the
Disclosing  Party,  return to the Disclosing  Party all drawings,  documents and
other  tangible  manifestations  of  Proprietary  Information  received  by  the
Recipient pursuant to this Agreement (and all copies and reproductions thereof),
except that the Recipient may retain one copy thereof  solely for the purpose of
determining the extent of its obligations hereunder.

         8. MISCELLANEOUS.

         (a) This Agreement  supersedes all prior  agreements,  written or oral,
between the Disclosing Party and the Recipient relating to the subject matter of
this  Agreement.  This Agreement may not be modif ed, changed or discharged,  in
whole or in part,  except by an  agreement in writing  signed by the  Disclosing
Party and the Recipient.

         (b) This Agreement will be binding upon and inure to the benefit of the
parties hereto and their respective heirs, successors and assigns.

         (c) The  obligations  and rights of the  parties  under this  Agreement
shall be governed by the internal  laws of the  Commonwealth  of  Massachusetts,
U.S.A., without reference to its conflict of laws rules.

         (d)  Each  party   acknowledges  that  disclosure  of  the  Proprietary
Information  of the other  party or use of the  Proprietary  Information  of the
other party  contrary to the  provisions  of this  Agreement  is likely to cause
irreparable  harm to the Disclosing Party for which damages at law may not be an
adequate  remedy,  and the Recipient  agrees that the Disclosing  Party shall be
entitled to  injunctive  relief to enjoin the

<PAGE>

breach of any provisions of this Agreement or to specifically enforce any of the
Recipient's obligations hereunder. Notwithstanding, but not in limitation of the
foregoing,  the Recipient  shall be responsible to the Disclosing  Party for any
damages  arising from the breach by the  Recipient of any of the  covenants  and
obligations  on its part to be observed or performed  under this  Agreement,  in
addition to any and all other remedies  available to the Disclosing Party at law
or in equity.

         (e) The parties shall adhere to the U.S. Export Administration Laws and
Regulations  and shall not export or re-export any technical  data received from
any other party  hereunder or the direct  product of such  technical data to any
proscribed country listed in the U.S. Export  Administration  Regulations unless
properly authorized by the U.S. Government.

         EXECUTED as a sealed  instrument as of the day and year first set forth
above.

                                      BioSyntech Limited

                                      By: /s/ Francois Binette
                                          -------------------------
                                              Francois Binette

                                      Title:  Vice President R&D

                                      Ontogeny, Inc.

                                      By:  /s/ Raul Rodriguez
                                           ------------------------
                                               Raul Rodriguez

                                      Title: Senior V.P., Business Development

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}]]